Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$4.22 USD

4.22
485,040

+0.01 (0.24%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $4.23 +0.01 (0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 9.09% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 7.25% and 8.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

by Zacks Equity Research

EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.

Zacks Equity Research

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.

Zacks Equity Research

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

by Zacks Equity Research

Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.

Zacks Equity Research

New Strong Buy Stocks for November 14th

by Zacks Equity Research

VNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024.

Zacks Equity Research

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

by Zacks Equity Research

VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.

Zacks Equity Research

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

by Zacks Equity Research

Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.

Zacks Equity Research

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

by Zacks Equity Research

Biohaven and Zevra are in the spotlight following positive updates on key candidates.

Zacks Equity Research

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

by Zacks Equity Research

The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.

Zacks Equity Research

Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

by Zacks Equity Research

Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.

Zacks Equity Research

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.

Zacks Equity Research

Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.

Zacks Equity Research

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

by Zacks Equity Research

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.

Zacks Equity Research

Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Vanda (VNDA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Vanda Pharmaceuticals (VNDA) concluded the recent trading session at $4.06, signifying a -1.46% move from its prior day's close.

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Vanda Pharmaceuticals (VNDA) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.

Zacks Equity Research

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

by Zacks Equity Research

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.